Centre for Eye Research Australia (CERA) - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/198002

Filters

2021 1
Reset filters

Settings
Statistics
Citations
Author: Bui, Bang × End date: 2021 × Start date: 2020 × Type: Journal Article ×

Search Results

Now showing 1 - 1 of 1
  • Item
    Thumbnail Image
    A drug-tunable Flt23k gene therapy for controlled intervention in retinal neovascularization
    Chen, J ; Lin, F-L ; Leung, JYK ; Tu, L ; Wang, J-H ; Chuang, Y-F ; Li, F ; Shen, H-H ; Dusting, GJ ; Wong, VHY ; Lisowski, L ; Hewitt, AW ; Bui, BV ; Zhong, J ; Liu, G-S (SPRINGER, 2021-02)
    Gene therapies that chronically suppress vascular endothelial growth factor (VEGF) represent a new approach for managing retinal vascular leakage and neovascularization. However, constitutive suppression of VEGF in the eye may have deleterious side effects. Here, we developed a novel strategy to introduce Flt23k, a decoy receptor that binds intracellular VEGF, fused to the destabilizing domain (DD) of Escherichia coli dihydrofolate reductase (DHFR) into the retina. The expressed DHFR(DD)-Flt23k fusion protein is degraded unless "switched on" by administering a stabilizer; in this case, the antibiotic trimethoprim (TMP). Cells transfected with the DHFR(DD)-Flt23k construct expressed the fusion protein at levels correlated with the TMP dose. Stabilization of the DHFR(DD)-Flt23k fusion protein by TMP was able to inhibit intracellular VEGF in hypoxic cells. Intravitreal injection of self-complementary adeno-associated viral vector (scAAV)-DHFR(DD)-Flt23k and subsequent administration of TMP resulted in tunable suppression of ischemia-induced retinal neovascularization in a rat model of oxygen-induced retinopathy (OIR). Hence, our study suggests a promising novel approach for the treatment of retinal neovascularization. Schematic diagram of the tunable system utilizing the DHFR(DD)-Flt23k approach to reduce VEGF secretion. a The schematic shows normal VEGF secretion. b Without the ligand TMP, the DHFR(DD)-Flt23k protein is destabilized and degraded by the proteasome. c In the presence of the ligand TMP, DHFR(DD)-Flt23k is stabilized and sequestered in the ER, thereby conditionally inhibiting VEGF. Green lines indicate the intracellular and extracellular distributions of VEGF. Blue lines indicate proteasomal degradation of the DHFR(DD)-Flt23k protein. Orange lines indicate the uptake of cell-permeable TMP. TMP, trimethoprim; VEGF, vascular endothelial growth factor; ER, endoplasmic reticulum.